Thu, Apr 17, 2014, 6:27 AM EDT - U.S. Markets open in 3 hrs 3 mins

Recent

% | $
Quotes you view appear here for quick access.

Delcath Systems, Inc. Message Board

  • haresh700707 haresh700707 Feb 11, 2013 11:53 AM Flag

    My Research on DCTH

    I was digging deeper into the history of this company and came across a few good article:

    1. Feb 22, 2011 - Adam Feuerstien
    Delcath drop 28% to $8.00 ...FDA issue "refuse to file" letter.... FDA requested information involving manufacturing plant inspection timing, product & sterilization valitation, and additional safety information.
    Note: more information about Phase III was not requested

    2. Oct 10, 2012 - Mark Messier - On 8-15-2012 Decalth requested priority review

    3. Oct 15, 2012 - Scott Donnelly - FDA accept Delcath application -- Delcath recieve a standard review apploval ...revenue could be as high as $2 Billion.......Phase 2 trial for patients with unresectable liver cancer ---- data show 70% of 20 patients showed a hepatic response after 3 treatments, whereas normalized response rate for these patients under current treatment arm would be 5%.

    I am still researching this company. Given the potential for $2B revenue and great phase II result, why is DCTH still trading at $1.5. At this point in time it should be around $10.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • tcracker09@ymail.com tcracker09 Feb 11, 2013 1:31 PM Flag

      $2B is a long ways off, initially, they will be in a 500 million market once FDA approval is given. Revenues in a 500 million market, once insurers reimburse, can put DCTH at a market cap double what it is now. It's going to take years. This stock could easily go to $10, and back down to $2.00 afterwards. GL

      Sentiment: Hold

 
DCTH
3.86+0.07(+1.85%)Apr 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.